We showed that A452, an HDAC6-selective inhibitor, rescues the phosphorylated levels of NF-kB, ERK, and STAT3 upregulated by BTZ resistance and induces cytotoxicity in BTZ-resistant MM cells. The gene discussed is NFKB1; the disease is Miyoshi myopathy.